| Autor: |
Kourie HR; Hematology-Oncology Department, Saint Joseph University of Beirut, Lebanon., Mahrous M; Prince Sultan Military Medical City, Riyadh, KSA.; Oncology Department, Minia University, Minia, Egypt., Naim N; Hematology-Oncology Department, Saint Joseph University of Beirut, Lebanon., Zouein J; Hematology-Oncology Department, Saint Joseph University of Beirut, Lebanon., Benbrahim Z; CHU Hassan II, Morocco., Rasul K; Natonal Center for Cancer Care & Research in Hamad Medical Corporation, Doha, Qatar., Mokhtar M; Director of Kasr Al Aini Oncology Unit, Cairo University, Egypt., Shehri AA; King Abdullah Medical City, Jeddah, KSA., Shakeeb M; Medical City Complex, Baghdad, Iraq., Khatib S; Secretary General of the Arab Medical Association Against Cancer, Jordan., Al-Shamsi H; President of the Emirates Oncology Society, Burjeel Cancer Institute & VPS Healthcare, UAE., Shamseddine A; Director of Gastrointestinal/Genitourinary Cancer Program at the Hematology-Oncology Division Basile Cancer Institute, American University of Beirut, Lebanon., Smyth E; Cambridge University Hospital, NHS Foundation Trust, Cambridge, UK. |
| Abstrakt: |
Gastric cancer (GC) ranks as the fifth most prevalent cancer and the fourth deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, GC represents about 4.8% of cancer cases with more than 35,000 new cases in 2020. To strengthen and improve the management of this cancer in the region, a group of MENA experts in the field of GC developed the first MENA consensus recommendations for the management of advanced GC. A total of 28 statements were drafted, discussed and voted on, using a modified Delphi process, during a virtual consensus meeting. The statements addressed the areas of epidemiology, biomarkers and treatment. |
